menu
Your Cart

ITT0929

  • Gene/Protein: CIITA
  • Product Description: Immunotag™ CIITA Polyclonal Antibody
  • 280.0000
    Price in reward points: 294

    Available Options

ITT0929

Immunotag™ CIITA Polyclonal Antibody
Antibody Specification
Datasheet
Target Protein CIITA
Clonality Polyclonal
Storage/Stability -20°C/1 year
Application WB,ELISA
Recommended Dilution Western Blot: 1/500 - 1/2000. ELISA: 1/10000. Not yet tested in other applications.
Concentration 1 mg/ml
Reactive Species Human,Mouse,Rat
Host Species Rabbit
Immunogen The antiserum was produced against synthesized peptide derived from human CIITA. AA range:706-755
Specificity CIITA Polyclonal Antibody detects endogenous levels of CIITA protein.
Purification The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen
Form Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Gene Name CIITA
Accession No. P33076 P79621
Alternate Names CIITA; MHC2TA; MHC class II transactivator; CIITA
Description class II major histocompatibility complex transactivator(CIITA) Homo sapiens This gene encodes a protein with an acidic transcriptional activation domain, 4 LRRs (leucine-rich repeats) and a GTP binding domain. The protein is located in the nucleus and acts as a positive regulator of class II major histocompatibility complex gene transcription, and is referred to as the "master control factor" for the expression of these genes. The protein also binds GTP and uses GTP binding to facilitate its own transport into the nucleus. Once in the nucleus it does not bind DNA but rather uses an intrinsic acetyltransferase (AT) activity to act in a coactivator-like fashion. Mutations in this gene have been associated with bare lymphocyte syndrome type II (also known as hereditary MHC class II deficiency or HLA class II-deficient combined immunodeficiency), increased susceptibility to rheumatoid arthritis, multiple sclerosis, and possibly myocardi
Cell Pathway/ Category Antigen processing and presentation,Primary immunodeficiency,
Subcellular Localization nucleoplasm,cell surface,PML body,
Protein Function disease:Defects in CIITA are a cause of bare lymphocyte syndrome type 2 (BLS2) [MIM:209920]; also known as hereditary MHC class II deficiency or HLA class II-deficient combined immunodeficiency. BLS2 is a severe combined immunodeficiency disease with early onset. It is characterized by a profound defect in constitutive and interferon-gamma induced MHC II expression, absence of cellular and humoral T-cell response to antigen challenge, hypogammaglobulinemia and impaired antibody production. The consequence include extreme susceptibility to viral, bacterial and fungal infections.,function:Essential for transcriptional activity of the HLA class II promoter; activation is via the proximal promoter. No DNA binding of in vitro translated CIITA was detected. May act in a coactivator-like fashion through protein-protein interactions by contacting factors binding to the proximal MHC class II promoter, to elements of the transcription machinery, or both. Alternatively it may activate HLA class II transcription by modifying proteins that bind to the MHC class II promoter.,online information:CIITA mutation db,similarity:Contains 1 NACHT domain.,similarity:Contains 4 LRR (leucine-rich) repeats.,subunit:Interacts with ZXDA and ZXDC.,
Usage For Research Use Only! Not for diagnostic or therapeutic procedures.
Material Safety Data Sheet
English_US
Danish
Dutch
English_UK
French
German
Spanish
Norwegian
Portuguese
Finnish
Swedish
Polish
Write a review
Note: HTML is not translated!
Bad Good
Captcha

Download our handbooks

Custom Services

Connect With Us

Stay up to date with G-Biosciences by signing up for our newsletter.